Topic resource collection
Approved comparison material connected to this topic.
774 resourcesRead both sides
Thymalin T-regulatory cell enhancement, thymic hormone restoration Animal models show increased CD4+CD25+ Treg populations (Immunology Letters, 2009) May modulate upstream immune dysregulation driving TRAb production No human tri…
Conventional AFib treatment targets symptom control: rate control drugs (beta-blockers, calcium channel blockers) slow AV nodal conduction; rhythm control drugs (flecainide, amiodarone, dofetilide) suppress ectopic beats and stab…
Before evaluating specific peptide compounds, understand that no peptide has FDA approval for interstitial cystitis treatment. The table below compares investigational peptides based on preclinical research mechanisms, not clinic…
Hormone replacement therapy works by binding to estrogen receptors (ERα and ERβ) throughout the body, including in the hypothalamus, reproductive tissues, bones, and cardiovascular system. This directly restores estrogen signalin…
BPC-157 VEGF receptor upregulation, collagen synthesis 200-500μg daily, 4-8 weeks Strong. Multiple animal models show 60-70% healing improvement Acute fascia tears, chronic fasciitis with vascular component First-line choice for …
Thymalin Immune modulation via thymulin upregulation Reduced inflammatory cytokines and improved CD4+/CD8+ ratios in men >60 with BPH (Advances in Gerontology, 2019) 10mg IM every other day × 10 doses Strongest evidence for immun…
Cerebrolysin Neurotrophic factor upregulation, reduced excitotoxicity TrkB (BDNF receptor), NMDA modulation IV infusion (clinical), SC (research models) −20°C lyophilised, 2–8°C reconstituted (14 days) Used in stroke, TBI. Migrai…
Thymalin Thymic peptide restoration Immune T-cell maturation, autoimmune regulation 10mg subcutaneous every 3–5 days, 10-injection cycle 10–14 days for immune marker changes Best option for perimenopause research focused on immun…
BPC-157 VEGF modulation, angiogenesis regulation, tissue repair Lesion neovascularisation, adhesion formation Preclinical only. In vitro and animal models Strongest theoretical basis for anti-adhesion effects; no human trials in …
Before choosing a research peptide, understanding the mechanism, evidence base, and practical constraints matters more than marketing claims. This table compares the most studied peptides for Sjogren's-related pathology. Thymalin…
Thymalin Thymic hormone restoration; stimulates T-cell maturation and thymulin production Increased CD4+/CD8+ counts, improved vaccine response, reduced infection rates in elderly subjects (clinical trials, St. Petersburg Institu…
GHK-Cu (Copper Peptide) Fibroblast activation, collagen/elastin gene upregulation, lysyl oxidase catalysis Type I/III collagen, elastin networks, decorin 1–3% in liposomal carrier 14.2% skin density increase in 12 weeks (J Drugs …
Thymalin (thymulin analog) Increases CD4+CD25+FoxP3+ Treg cells Restores T-cell balance away from TH2 dominance Preclinical murine models No Phase 3 human trials for allergy indications. Dosing protocols undefined KPV (Lys-Pro-Va…
Before interpreting this table, understand that peptide research in postpartum populations is limited. Most evidence comes from wound healing, immune reconstitution, or metabolic studies in other contexts, with postpartum applica…
This table compares the five peptides with the strongest preclinical and clinical evidence for neuropathic pain relief based on mechanism, onset, and research-demonstrated efficacy. BPC-157 VEGF upregulation, nitric oxide signali…
BPC-157 VEGF upregulation, angiogenesis, collagen alignment 200–500 mcg/day subcutaneous near injury site Subcutaneous, 2–3 inches from injury Reduces healing time by 30–40% in research models Best choice for acute ligament tears…
BPC-157 VEGF upregulation, nitric oxide synthesis Angiogenesis, gingival wound closure Strong preclinical (rat/dog models), no human RCTs for periodontitis 200–500 mcg SC or topical gel, 2–3× weekly Best evidence for direct vascu…
Before selecting a peptide for CTE research, compare the molecular targets each compound addresses, the dosing schedules validated in published TBI models, and the known limitations that affect reproducibility. | Peptide | Primar…
Thymalin T-cell regulation, cytokine modulation Neuroinflammation (IL-6, TNF-α) Subcutaneous 6–8 hours Best evidence for immune normalization in neuroimmune models; requires multi-week administration Cerebrolysin BDNF/NGF mimetic…
Cerebrolysin BDNF/NGF mimetic; enhances neurotrophic signaling in hippocampus and amygdala Yes (receptor-mediated transcytosis) 0.5–2.0 mL/kg IM daily × 10–21 days 40–60% increase in hippocampal BDNF mRNA; improved fear extinctio…